-
L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production
-
Lack of depotentiation may not be a hallmark of Levodopa-induced dyskinesias
-
Lack of sensitivity of full-depth upper gastrointestinal specimens as a prodromal biomarker for synucleinopathy in idiopathic REM sleep behavior disorder
-
Large-Scale Network Changes in the Pathophysiology of Essential Tremor
-
Laryngeal movement disorders as a potential clinical biomarker in multiple system atrophy: Results from the LaPD study
-
Late onset Wilson’s disease with hepatic and neurological manifestations
-
Late-Onset Dopa-Responsive Dystonia: A Case Report
-
Left-right motor cortex asymmetry in the pathophysiology of essential tremor
-
Leveraging patient-specific models to optimize DBS monopolar review
-
Levodopa and dopamine agonists dosage changes after Opicapone introduction
-
Levodopa Challenge Test for Prediction of Deep Brain Stimulation Efficacy on Motor Functions for Parkinson’s Disease
-
Levodopa Changes Functional Connectivity Patterns in Subregions of the Primary Motor Cortex in Patients with Parkinson’s Disease
-
Levodopa Dose Equivalency for Opicapone and Safinamide
-
Levodopa improves tremor symptom by reducing the connectivity between the thalamic subregions and postcentral gyrus in patients with Parkinson’s disease
-
Levodopa induced changes of tongue body movements during speech production
-
Levodopa-induced dyskinesias and substantia nigra dopamine D3 receptor availability in Parkinson’s disease
-
LFP in motor subtypes of Parkinson’s disease
-
Linguistic Deficits in Patients with Parkinson’s Disease
-
LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression
-
Loneliness/Social Isolation as a Risk Factor for Worsened Parkinson Disease Severity
-
Long and short survival in Parkinson syndrome: pathology and genetics are key prognostic factors
-
Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
-
Long-term course and confounding factors of MDS-UPDRS in a longitudinal single-center (DeNoPa) and a multicenter cohort (PPMI)
-
Long-term course of a case with primary orthostatic tremor
-
Long-term effect of deep brain stimulation in a monkey model of Parkinson’s disease with L-Dopa–induced dyskinesias
-
Long-term effect of non-invasive Vagus Nerve Stimulation in Parkinson’s disease patients
-
Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
-
Long-term effects of air pollution on the risk of Parkinson’s disease
-
Long-term quality of life after subthalamic deep brain stimulation depends on non-motor symptoms in Parkinson’s disease
-
Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
-
Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study
-
Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
-
Longitudinal association between UPDRS and health-related quality of life in people with Parkinson´s disease
-
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
-
Longitudinal clinical and imaging characteristics of non-manifest LRRK2 carriers: The PPMI cohort
-
Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington’s disease: the prospective HD-CSF study
-
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients and controls: the PPMI study
-
Longitudinal Utility of the Montreal Cognitive Assessment and Mini Mental State Exam in Huntington’s disease (HD)
-
Look Again: The Diagnostic Value of Repeat Dopamine Transporter Imaging
-
Loss of CHCHD2 and CHCHD10 disrupts mitochondrial cristae phenocopying patient mutations
-
Loss of cortical inhibition in Parkinson’s disease
-
Loss of Weight Associated with Levodopa / Carbidopa Intestinal Gel
-
Loss‐of‐function mutations in NR4A2 cause dopa‐responsive dystonia-parkinsonism
-
Low dose Cabergoline for freezing of gait in advanced Parkinson’s disease – you can have your cake and eat it too!
-
Low Educational Level and Wilson’s disease: A direct path to cognitive decline
-
Low Intensity Cycling Combined with Blood Flow Restriction as a Feasible Strategy for Improving Motor Function in Parkinson’s Disease- A Single Case Study
-
LRRK2 p.G2019S and p.N2081D variants as modifiers of glucocerebrosidase activity
-
LSVT LOUD Applied to Adults with Cerebral Palsy: Two Single-Subject Studies
MDS Virtual Congress 2020
September 12-16, 2020. Virtual Congress. www.mdscongress.org